3 Top Pharma Stocks To Buy This Month

Novo Nordisk A/S (NVO

NVO is the leading provider of diabetes-care products globally, with a 50% market share of the global insulin market and a 28% share of the $50 billion-plus diabetes treatment market. The company manufactures and markets various human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents.

NVO also has a biopharmaceutical segment that specializes in protein therapies for hemophilia and other disorders. The company is expected to benefit for the foreseeable future as the prevalence of diabetes is skyrocketing due to an increasingly overweight and aging population. Plus, the diabetes market is shifting from human insulin toward modern insulin analogs, including the company’s Levemir and NovoLog treatments.

These modern treatments offer improved convenience, efficacy, and safety for patients. NVO also sees growth in GLP-1 therapies, including the company’s daily Victoza drug, weekly Ozempic drug, and Rybelsus. The GLP-1 market is expected to double over the next five years. NVO has an overall grade of A, translating into a Strong Buy rating in our POWR Ratings system.

The company has a Value Grade of B, which isn’t surprising with a price-to-sales ratio of 9.3, which is well below the industry average. NVO also has a Quality Grade of A, which means it has a rock-solid balance sheet. In addition to a net profit margin of 33.8%, the company’s debt to equity ratio of 0.2 is quite low. To access all of NVO’s grades, click here. NVO is ranked #3 in the Medical – Pharmaceuticals industry.

Want More Great Investing Ideas?

7 SEVERELY Undervalued Stocks

9 "Must Own" Growth Stocks for 2021

How to Trade The NEW Stock Market Bubble?

5 Ways to Beat the S&P 500


BMY shares. Year-to-date, BMY has gained 3.49%, versus a 13.32% rise in the benchmark S&P 500 index during the same period.

1 2 3
View single page >> |

Disclaimer: Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use, please ...

more
How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.
Roger Keats 1 month ago Member's comment

good overall summation of these stocks